it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done..
.
phil lempert: it's affordability. it's convenience. it's not having a lot of waste. people are more concerned about waste than ever before..
.
share on google plus google-plus
.treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk (file pic).-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018..
subscribe today to be the first to to know about breaking news and special reports.